Lenz Therapeutics Stock Analysis
| LENZ Stock | 33.02 0.94 2.77% |
LENZ Therapeutics is fairly valued with Real Value of 29.6 and Target Price of 34.0. The main objective of LENZ Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what LENZ Therapeutics is worth, separate from its market price. There are two main types of LENZ Therapeutics' stock analysis: fundamental analysis and technical analysis.
The LENZ Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. LENZ Therapeutics is usually not traded on Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day. LENZ Stock trading window is adjusted to America/New York timezone.
LENZ |
LENZ Stock Analysis Notes
About 86.0% of the company shares are owned by institutional investors. The book value of LENZ Therapeutics was now reported as 7.46. The company recorded a loss per share of 2.74. LENZ Therapeutics last dividend was issued on the 21st of March 2024. The entity had 1:7 split on the 22nd of March 2024. To find out more about LENZ Therapeutics contact Evert Schimmelpennink at (858) 925-7000 or learn more at https://www.lenz-tx.com.LENZ Therapeutics Investment Alerts
| LENZ Therapeutics appears to be risky and price may revert if volatility continues | |
| LENZ Therapeutics was previously known as Graphite Bio and was traded on NASDAQ Exchange under the symbol GRPH. | |
| Net Loss for the year was (124.65 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| LENZ Therapeutics generates negative cash flow from operations | |
| LENZ Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Over 86.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: LENZ Therapeutics Shares Down 6.2 percent Time to Sell |
LENZ Largest EPS Surprises
Earnings surprises can significantly impact LENZ Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-08-15 | 2024-06-30 | -0.49 | -0.4 | 0.09 | 18 | ||
2024-02-27 | 2023-12-31 | -0.13 | -0.4 | -0.27 | 207 | ||
2023-05-11 | 2023-03-31 | -2.32 | -3.01 | -0.69 | 29 |
LENZ Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 600.49 M.LENZ Profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.66) | (0.69) | |
| Return On Capital Employed | (0.40) | (0.38) | |
| Return On Assets | (0.66) | (0.69) | |
| Return On Equity | (0.68) | (0.65) |
Management Efficiency
LENZ Therapeutics has return on total asset (ROA) of (0.7717) % which means that it has lost $0.7717 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.5761) %, meaning that it created substantial loss on money invested by shareholders. LENZ Therapeutics' management efficiency ratios could be used to measure how well LENZ Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.69 in 2024. Return On Capital Employed is likely to rise to -0.38 in 2024. At this time, LENZ Therapeutics' Total Assets are fairly stable compared to the past year. Total Current Assets is likely to rise to about 190.6 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 413.2 K in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 22.54 | 16.95 | |
| Tangible Book Value Per Share | 22.54 | 16.95 | |
| Enterprise Value Over EBITDA | 0.69 | 0.73 | |
| Price Book Value Ratio | 0.55 | 0.58 | |
| Enterprise Value Multiple | 0.69 | 0.73 | |
| Price Fair Value | 0.55 | 0.58 | |
| Enterprise Value | -84.5 M | -80.3 M |
Leadership effectiveness at LENZ Therapeutics is a strong indicator of its financial stability. We analyze various metrics to provide insights into the stock's investment viability.
Forward Dividend Yield 0.8912 | Return On Assets (0.77) | Return On Equity (1.58) |
Technical Drivers
As of the 13th of December 2024, LENZ Therapeutics secures the mean deviation of 3.51, and Risk Adjusted Performance of 0.1003. In connection with fundamental indicators, the technical analysis model lets you check helpful technical drivers of LENZ Therapeutics, as well as the relationship between them.LENZ Therapeutics Price Movement Analysis
java.lang.NullPointerException: Cannot invoke "java.lang.Number.intValue()" because the return value of "sun.invoke.util.ValueConversions.primitiveConversion(sun.invoke.util.Wrapper, Object, boolean)" is null. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. LENZ Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for LENZ Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
LENZ Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific LENZ Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on LENZ Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases LENZ Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
LENZ Therapeutics Predictive Daily Indicators
LENZ Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of LENZ Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
LENZ Therapeutics Forecast Models
LENZ Therapeutics' time-series forecasting models are one of many LENZ Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary LENZ Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About LENZ Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how LENZ Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling LENZ shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as LENZ Therapeutics. By using and applying LENZ Stock analysis, traders can create a robust methodology for identifying LENZ entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (6.06) | (6.37) | |
| Operating Profit Margin | (6.34) | (6.66) | |
| Net Loss | (6.06) | (6.37) | |
| Gross Profit Margin | 0.40 | 0.35 |
Current LENZ Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. LENZ analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. LENZ analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Advice | # of Analysts | |
| 34.0 | Strong Buy | 7 | Odds |
Most LENZ analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand LENZ stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of LENZ Therapeutics, talking to its executives and customers, or listening to LENZ conference calls.
LENZ Stock Analysis Indicators
LENZ Therapeutics stock analysis indicators help investors evaluate how LENZ Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading LENZ Therapeutics shares will generate the highest return on investment. By understating and applying LENZ Therapeutics stock analysis, traders can identify LENZ Therapeutics position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 47.7 M | |
| Common Stock Shares Outstanding | 8.1 M | |
| Total Stockholder Equity | 183.6 M | |
| Free Cash Flow | -100.9 M | |
| Property Plant And Equipment Net | 321 K | |
| Cash And Short Term Investments | 185.9 M | |
| Cash | 185.9 M | |
| Other Current Assets | 2.2 M | |
| Accounts Payable | 250 K | |
| Net Debt | -185.5 M | |
| 50 Day M A | 22.4974 | |
| Total Current Liabilities | 4.8 M | |
| Other Operating Expenses | 73.1 M | |
| Non Current Assets Total | 435 K | |
| Liabilities And Stockholders Equity | 188.5 M |
Additional Tools for LENZ Stock Analysis
When running LENZ Therapeutics' price analysis, check to measure LENZ Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy LENZ Therapeutics is operating at the current time. Most of LENZ Therapeutics' value examination focuses on studying past and present price action to predict the probability of LENZ Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move LENZ Therapeutics' price. Additionally, you may evaluate how the addition of LENZ Therapeutics to your portfolios can decrease your overall portfolio volatility.